Published in Mol Clin Oncol on April 05, 2016
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol (1996) 2.68
Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst (2009) 2.45
Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology (2006) 2.28
Hepatitis B virus genetic variability and evolution. Virus Res (2007) 1.80
Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res (2001) 1.57
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol (2006) 1.40
Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol (2008) 1.30
Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol (2007) 1.23
Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett (2010) 1.22
Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis (2008) 1.20
Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Arch Virol (1999) 1.16
Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection. J Med Virol (2008) 1.15
Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol (2007) 1.14
Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene (2000) 1.07
Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat (2014) 0.99
Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China. Int J Clin Exp Pathol (2013) 0.99
Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol (2009) 0.98
Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis. Med Mol Morphol (2009) 0.93
Modulation of apoptotic signaling by the hepatitis B virus X protein. Viruses (2012) 0.93
Synergistic effects of A1896, T1653 and T1762/A1764 mutations in genotype c2 hepatitis B virus on development of hepatocellular carcinoma. J Viral Hepat (2012) 0.92
[Epidemiology, natural history, and risk factors of hepatocellular carcinoma]. Rev Prat (2013) 0.90
Mutations of the X region of hepatitis B virus and their clinical implications. Pathol Int (1997) 0.90
Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. J Med Virol (1995) 0.89
X gene mutations in hepatitis B patients with cirrhosis, with and without hepatocellular carcinoma. J Med Virol (2009) 0.87
Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. J Viral Hepat (2007) 0.85
Hepatitis B virus X protein mutant upregulates CENP-A expression in hepatoma cells. Oncol Rep (2011) 0.84
A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int (2010) 0.84
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. Liver Int (2013) 0.82
Update on new approaches in the management of hepatocellular carcinoma. Hepat Med (2010) 0.77